Cambridge Investment Research Advisors
NKTR icon

Cambridge Investment Research Advisors’s Nektar Therapeutics NKTR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.03M Buy
56,055
+2,342
+4% +$133K 0.01% 1094
2025
Q4 		$2.27M Buy
53,713
+7,077
+15% +$396K 0.01% 1421
2025
Q3 		$2.65M Buy
46,636
+34,554
+286% +$1.14M 0.01% 1294
2025
Q2 		$312K Buy
12,082
+3,017
+33% +$33.9K ﹤0.01% 2945
2025
Q1 		$92K Buy
9,065
+615
+7% +$8.04K ﹤0.01% 3358
2024
Q4 		$118K Sell
8,450
-362
-4% -$6.38K ﹤0.01% 3307
2024
Q3 		$172K Buy
8,812
+620
+8% +$11.8K ﹤0.01% 3191
2024
Q2 		$152K Sell
8,192
-209
-2% -$4.41K ﹤0.01% 3102
2024
Q1 		$118K Sell
8,401
-260
-3% -$2.72K ﹤0.01% 3133
2023
Q4 		$73K Sell
8,661
-318
-4% -$2.41K ﹤0.01% 3070
2023
Q3 		$80K Sell
8,979
-151
-2% -$1.45K ﹤0.01% 2992
2023
Q2 		$79K Sell
9,130
-14
-0.2% -$149 ﹤0.01% 3039
2023
Q1 		$96K Buy
9,144
+329
+4% +$9.95K ﹤0.01% 2970
2022
Q4 		$299K Buy
+8,815
New +$427K ﹤0.01% 2432
2021
Q3 		– Sell
-686
Closed -$177K – 3160
2021
Q2 		$177K Sell
686
-2
-0.3% -$554 ﹤0.01% 2869
2021
Q1 		$206K Sell
688
-29
-4% -$9.03K ﹤0.01% 2598
2020
Q4 		$183K Sell
717
-74
-9% -$19.1K ﹤0.01% 2500
2020
Q3 		$197K Buy
791
+1
+0.1% +$315 ﹤0.01% 2241
2020
Q2 		$275K Sell
790
-60
-7% -$18.7K ﹤0.01% 1951
2020
Q1 		$227K Sell
850
-37
-4% -$11.4K ﹤0.01% 1850
2019
Q4 		$287K Sell
887
-89
-9% -$25.8K ﹤0.01% 1937
2019
Q3 		$267K Buy
976
+8
+0.8% +$2.93K ﹤0.01% 1910
2019
Q2 		$517K Buy
968
+81
+9% +$40.6K ﹤0.01% 1401
2019
Q1 		$447K Buy
887
+184
+26% +$109K ﹤0.01% 1565
2018
Q4 		$347K Sell
703
-89
-11% -$53.7K ﹤0.01% 1563
2018
Q3 		$724K Buy
792
+473
+148% +$404K 0.01% 1225
2018
Q2 		$234K Buy
319
+68
+27% +$78.4K ﹤0.01% 1900
2018
Q1 		$400K Buy
251
+7
+3% +$9.02K ﹤0.01% 1468
2017
Q4 		$219K Buy
+244
New +$144K ﹤0.01% 1866

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cambridge Investment Research Advisors's NKTR Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its Nektar Therapeutics (NKTR) stake by 4.4% in Q1 2026, buying an estimated $133K and bringing the position to 56,055 shares worth $4.03M. The position accounts for 0.01% of the portfolio, ranked #1094.

Cambridge Investment Research Advisors first reported a position in NKTR in Q4 2017 and has held it in 29 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Cambridge Investment Research Advisors held 56,055 shares of Nektar Therapeutics worth $4.03M as of Q1 2026.
  • Cambridge Investment Research Advisors bought 2,342 Nektar Therapeutics shares in Q1 2026, an estimated $133K.
  • Nektar Therapeutics made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #1094 holding.
  • Cambridge Investment Research Advisors first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 29 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.